Cargando…

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

This report constitutes a prospectively planned meta-analysis combining two almost identical trials undertaken in Australasia and Canada to study the effect of starting chemotherapy immediately in asymptomatic patients with metastatic colorectal cancer. Patients (n=168) were randomised to receive ei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ackland, S P, Jones, M, Tu, D, Simes, J, Yuen, J, Sargeant, A-M, Dhillon, H, Goldberg, R M, Abdi, E, Shepherd, L, Moore, M J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2005
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361520/ https://www.ncbi.nlm.nih.gov/pubmed/16265352 http://dx.doi.org/10.1038/sj.bjc.6602841

Ejemplares similares

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
por: Di Fiore, F, et al.
Publicado: (2007)

Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study
por: Österlund, P, et al.
Publicado: (2007)

A systematic review of taxane-containing regimens for metastatic breast cancer
por: Ghersi, D, et al.
Publicado: (2005)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
por: Conroy, T, et al.
Publicado: (2010)

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
por: Okines, A, et al.
Publicado: (2009)

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
por: Townsley, C A, et al.
Publicado: (2006)

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer
por: Lee, C K, et al.
Publicado: (2010)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
por: Seymour, Matthew T, et al.
Publicado: (2011)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study
por: De Placido, S, et al.
Publicado: (2005)

A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)
por: Stebbing, J, et al.
Publicado: (2008)

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
por: Leong, Trevor, et al.
Publicado: (2015)

The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer
por: Ward, S E, et al.
Publicado: (2006)

Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy
por: Wengström, Y., et al.
Publicado: (2017)

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
por: Graziano, F, et al.
Publicado: (2008)

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
por: Peeters, M, et al.
Publicado: (2013)

Randomised controlled trial of a supervised exercise rehabilitation program for colorectal cancer survivors immediately after chemotherapy: study protocol
por: Spence, Rosalind R, et al.
Publicado: (2007)

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
por: Van Cutsem, E, et al.
Publicado: (2005)

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2010)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer
por: Shi, Min, et al.
Publicado: (2020)

Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]
por: Roberts, Christine L, et al.
Publicado: (2011)

A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer
por: Dreosti, Lydia M., et al.
Publicado: (2014)

Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
por: de Takats, P. G., et al.
Publicado: (1994)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer
por: Khan, O A, et al.
Publicado: (2008)

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
por: Aparicio, T, et al.
Publicado: (2003)

Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer
por: Midthun, Lauren, et al.
Publicado: (2022)

Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study
por: Maddalena, Chiara, et al.
Publicado: (2021)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
por: Lim, S H, et al.
Publicado: (2015)

Evaluation of an Australian health literacy training program for socially disadvantaged adults attending basic education classes: study protocol for a cluster randomised controlled trial
por: McCaffery, Kirsten J., et al.
Publicado: (2016)

The beneficial effect of palliative resection in metastatic colorectal cancer
por: Park, J H, et al.
Publicado: (2013)

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone
por: Mirnezami, R, et al.
Publicado: (2014)

Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study
por: Bork, U, et al.
Publicado: (2015)

Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy
por: Zhang, Hang-Yu, et al.
Publicado: (2018)

Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis
por: Hur, H, et al.
Publicado: (2012)

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
por: Hall, P S, et al.
Publicado: (2017)

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
por: Glynne-Jones, R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4kqsapck8mi7kkd9vbh72uh1sc